Seven drug targets for sarcopenia mapped the same week the first drug against one of them won FDA approval
Seven drug targets for sarcopenia mapped the same week the first drug against one of them won FDA approval
On 7 September 2026, Nature Reviews Drug Discovery published a review presenting the first map of seven pharmacological mechanisms against sarcopenia, the age-related loss of muscle mass and strength for which no approved drug exists. Four days later, on 11 September, the FDA for the first time approved apitegromab, a Scholar Rock compound that blocks myostatin, a protein that inhibits muscle growth, for spinal muscular atrophy. That same week, trial data showed that apitegromab combined with tirzepatide nearly halved muscle loss during weight reduction.
Sarcopenia is a distinct diagnosis: after age 50 a person loses roughly 10% of muscle mass per decade, and between 40 and 80 the cumulative loss ranges from one third to one half. Recognition came late. The diagnostic code appeared only in 2016, and the clinical definition followed in 2019; without them there were neither insurance pathways nor trial entry criteria. Yet no drug has emerged, because the disease has several concurrent drivers: cellular energy production declines, the stem cells that repair tissue become depleted, the nerve connections to muscle fibers thin out, and perivascular inflammation rises. For this reason the review identifies seven independent treatment mechanisms, each aimed at one of these processes.
Muscle does not weaken uniformly. Fast-twitch fibers, responsible for strength and explosive movement, lose about 40% of their size, while slow-twitch fibers remain nearly unchanged. Muscle stem cells decline by 24% in women and 37% in men with aging, and roughly two thirds of the surviving cells function poorly. The authors label some of these processes "gerozymes," enzymes that become more active with age and break down substances the tissue needs for repair. A discovery from Helen Blau's laboratory at Stanford identified the enzyme 15-PGDH: in old mice, suppressing it rejuvenated muscle, intestine, kidney, and lung tissue, and in an Alzheimer's disease model it even improved memory. In 28-month-old mice, which are very old for the species, a blocker of the same enzyme restored the muscle's ability to grow in response to exercise: strength increased by nearly 50% more than in untreated animals.
Myostatin blockade is the most clinically advanced of the seven mechanisms. On 11 September, apitegromab became the first approved myostatin blocker in history. The approval was not for sarcopenia but for spinal muscular atrophy, a condition in which earlier drugs protected motor neurons but did nothing for the muscle itself. "After decades of failed attempts across the entire industry to unlock the potential of myostatin blockade, Scholar Rock has achieved a therapeutic breakthrough," said the company's CEO, David Bhatt.
The review identifies a central problem: in humans, unlike mice, the mass gains from anti-myostatin antibodies translate poorly into strength gains, with only a 3–9% increase in mass and limited improvement in muscle function. A more widespread threat to muscle comes from weight-loss drugs themselves. Tirzepatide and related agents produce 25–30% fat mass loss, but muscle mass is lost alongside the fat and recovers more slowly than fat after the drug is stopped. The review does not mention the apitegromab-plus-tirzepatide combination directly but describes the same trend in other pairings; according to the EMBRAZE trial data, this combination preserved 54.9% more lean mass over 24 weeks than tirzepatide alone. A cheaper alternative is being tested at Vanderbilt University: an HMB plus vitamin D3 supplement for older adults starting semaglutide.
Sarcopenia was long regarded as simply part of aging. Over the past decade it has acquired a diagnostic code, a map of seven drug targets, and the first approved mechanism of action. The gap between mass gain and strength gain remains the open problem highlighted by the review.